3,4-dihydroxyphenylacetic acid has been researched along with Disease Exacerbation in 19 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dopamine levels may not directly modulate the refractive state of the mouse eye, but tonic levels of dopamine during development may determine susceptibility to myopia." | 3.80 | Visually-driven ocular growth in mice requires functional rod photoreceptors. ( Abey, J; Aseem, F; Iuvone, PM; Jabbar, SB; Pardue, MT; Park, Hn; Schmid, G; Sidhu, CS; Tan, CC, 2014) |
| "Current research on Parkinson's disease (PD) pathogenesis requires relevant animal models that mimic the gradual and progressive development of neuronal dysfunction and degeneration that characterizes the disease." | 1.42 | Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. ( Beauvais, G; Brundin, P; Escobar Galvis, ML; Feinstein, TN; Fuchs, J; Ghosh, A; Joshi, RL; Lipton, JW; Lundblad, M; Medicetty, S; Nordströma, U; Prochiantz, A; Pulikkaparambil Sasidharan, BC; Roholt, A; Steiner, JA, 2015) |
| "Our data show that disease progression produces an early large decay of DA levels, followed by a stabilization." | 1.35 | Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. ( Brusa, L; Fedele, E; Fornai, F; Galati, S; Hainsworth, AH; Lunardi, G; Moschella, V; Pierantozzi, M; Pisani, A; Rossi, S; Stanzione, P; Stefani, A; Tropepi, D, 2009) |
| "Ten patients with advanced Parkinson's disease (Hoehn & Yahr stage IV) were medicated with tolcapone." | 1.31 | COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. ( Buhmann, C; Oechsner, M; Strauss, J; Stuerenburg, HJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| van der Sande, E | 1 |
| Polling, JR | 1 |
| Tideman, JWL | 1 |
| Meester-Smoor, MA | 1 |
| Thiadens, AAHJ | 1 |
| Tan, E | 1 |
| De Zeeuw, CI | 1 |
| Hamelink, R | 1 |
| Willuhn, I | 1 |
| Verhoeven, VJM | 1 |
| Winkelman, BHJ | 1 |
| Klaver, CCW | 1 |
| Kao, CY | 1 |
| Xu, M | 1 |
| Wang, L | 1 |
| Lin, SC | 1 |
| Lee, HJ | 1 |
| Duraine, L | 1 |
| Bellen, HJ | 1 |
| Goldstein, DS | 2 |
| Tsai, SY | 1 |
| Tsai, MJ | 1 |
| Sasidharakurup, H | 1 |
| Melethadathil, N | 1 |
| Nair, B | 1 |
| Diwakar, S | 1 |
| Holmes, C | 1 |
| Lopez, GJ | 1 |
| Wu, T | 1 |
| Sharabi, Y | 1 |
| Park, Hn | 2 |
| Jabbar, SB | 1 |
| Tan, CC | 1 |
| Sidhu, CS | 1 |
| Abey, J | 1 |
| Aseem, F | 1 |
| Schmid, G | 1 |
| Iuvone, PM | 2 |
| Pardue, MT | 2 |
| Nordströma, U | 1 |
| Beauvais, G | 1 |
| Ghosh, A | 1 |
| Pulikkaparambil Sasidharan, BC | 1 |
| Lundblad, M | 1 |
| Fuchs, J | 1 |
| Joshi, RL | 1 |
| Lipton, JW | 1 |
| Roholt, A | 1 |
| Medicetty, S | 1 |
| Feinstein, TN | 1 |
| Steiner, JA | 1 |
| Escobar Galvis, ML | 1 |
| Prochiantz, A | 1 |
| Brundin, P | 1 |
| Kim, AR | 1 |
| Ugryumov, MV | 1 |
| Bergen, MA | 1 |
| Chakraborty, R | 1 |
| Landis, EG | 1 |
| Sidhu, C | 1 |
| He, L | 1 |
| Lunardi, G | 1 |
| Galati, S | 1 |
| Tropepi, D | 1 |
| Moschella, V | 1 |
| Brusa, L | 1 |
| Pierantozzi, M | 1 |
| Stefani, A | 1 |
| Rossi, S | 1 |
| Fornai, F | 1 |
| Fedele, E | 1 |
| Stanzione, P | 1 |
| Hainsworth, AH | 1 |
| Pisani, A | 1 |
| Zádori, D | 1 |
| Geisz, A | 1 |
| Vámos, E | 1 |
| Vécsei, L | 1 |
| Klivényi, P | 1 |
| Meng, T | 1 |
| Zheng, ZH | 1 |
| Liu, TT | 1 |
| Lin, L | 1 |
| Tillerson, JL | 1 |
| Cohen, AD | 1 |
| Caudle, WM | 1 |
| Zigmond, MJ | 1 |
| Schallert, T | 1 |
| Miller, GW | 1 |
| de Lago, E | 1 |
| Fernández-Ruiz, J | 1 |
| Ortega-Gutiérrez, S | 1 |
| Cabranes, A | 1 |
| Pryce, G | 1 |
| Baker, D | 1 |
| López-Rodríguez, M | 1 |
| Ramos, JA | 1 |
| Teicher, MH | 1 |
| Andersen, SL | 1 |
| Campbell, A | 1 |
| Gelbard, HA | 1 |
| Baldessarini, RJ | 1 |
| Bezard, E | 1 |
| Dovero, S | 1 |
| Prunier, C | 1 |
| Ravenscroft, P | 1 |
| Chalon, S | 1 |
| Guilloteau, D | 1 |
| Crossman, AR | 1 |
| Bioulac, B | 1 |
| Brotchie, JM | 1 |
| Gross, CE | 1 |
| Barthwal, MK | 1 |
| Srivastava, N | 1 |
| Dikshit, M | 1 |
| Rebec, GV | 1 |
| Barton, SJ | 1 |
| Ennis, MD | 1 |
| Oechsner, M | 1 |
| Buhmann, C | 1 |
| Strauss, J | 1 |
| Stuerenburg, HJ | 1 |
| Kirik, D | 1 |
| Rosenblad, C | 1 |
| Burger, C | 1 |
| Lundberg, C | 1 |
| Johansen, TE | 1 |
| Muzyczka, N | 1 |
| Mandel, RJ | 1 |
| Björklund, A | 1 |
19 other studies available for 3,4-dihydroxyphenylacetic acid and Disease Exacerbation
| Article | Year |
|---|---|
Myopia control in Mendelian forms of myopia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Atropine; Disease Progression; Female; Humans; Male; Mice; | 2023 |
Elevated COUP-TFII expression in dopaminergic neurons accelerates the progression of Parkinson's disease through mitochondrial dysfunction.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Brain; Cell Line; Cell Line, Tumor; | 2020 |
A Systems Model of Parkinson's Disease Using Biochemical Systems Theory.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Biomarkers; Brain; Cell Death; Computer Simulation; | 2017 |
Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Biomarkers; Disease Progression; Dopamine; Female; Foll | 2018 |
Visually-driven ocular growth in mice requires functional rod photoreceptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Disease Models, Anima | 2014 |
Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autophagy; Corpus Striatum; Disease Models, Animal; Disease | 2015 |
Changes in plasma catecholamines levels as preclinical biomarkers in experimental models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Blood Chemical Analysis; Chromatography, High P | 2015 |
Altered Refractive Development in Mice With Reduced Levels of Retinal Dopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Biomarkers; Disease Models, Animal; Disease Progress | 2016 |
Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age of Onset; Aged; Disease Progression; Dopamine; Dyskinesias; Homo | 2009 |
Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2009 |
Contralateral retinal dopamine decrease and melatonin increase in progression of hemiparkinsonium rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Disease Progression; | 2012 |
Forced nonuse in unilateral parkinsonian rats exacerbates injury.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Casts, Surg | 2002 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D | 2006 |
Progressive accumbens degeneration after neonatal striatal 6-hydroxydopamine in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Caudate Nucleus; Chromatography, High Pre | 1998 |
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiograp | 2001 |
Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; | 2001 |
Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Ascorbic Acid; Behavior, Animal; Body Weight; Corpus Striat | 2002 |
COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catech | 2002 |
Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Behavior, Animal; Cell Count; Cell Death; | 2002 |